Table 1

Results from segmented regression analyses of rate of prescribing in the UK in 4–18 year olds

Base level (β0)
(95% CI)
P valueBase trend (β1)
(95% CI)
P valuePost-CSM intervention (β2)
(95% CI)
P valuePost-CSM change in trend (β3)
(95% CI)
P valuePost-NICE intervention (β4)
(95% CI)
P valuePost-NICE change in trend (β5)
(95% CI)
P value
NICE cited SSRIs232.70
(184.33 to 281.07)
<0.0015.24
(3.43 to 7.05)
<0.001−107.94
(−194.72 to − 21.15)
0.02−12.34
(−18.67 to − 6.00)
<0.00152.72
(−34.95, 140.40)
0.2411.52
(5.32 to 17.73)
<0.001
Fluoxetine144.26
(112.62 to 175.90)
<0.0012.10
(0.92 to 3.29)
0.00158.71
(1.94 to 115.48)
0.04−8.69
(−12.83 to − 4.54)
<0.00160.06
(2.71 to 117.41)
0.047.97
(3.91 to 12.03)
<0.001
Citalopram75.61
(47.99 to 103.22)
<0.0012.89
(1.85 to 3.92)
<0.001−84.94
(−134.49 to − 35.40)
0.001−4.65
(−8.27 to − 1.03)
0.0144.40
(−5.56, 94.35)
0.085.52
(1.98 to 9.06)
0.002
Sertraline13.31
(− 3.67 to 30.29)
0.122.30
(1.67 to 2.93)
<0.001−62.57
(−92.24 to − 32.90)
<0.001−3.26
(−5.43 to − 1.09)
0.003−16.02
(−45.84, 13.80)
0.292.51
(0.39 to 4.62)
0.02
Non-NICE SSRIs116.40
(100.89 to 131.91)
<0.001−0.25
(−0.83, 0.34)
0.41−37.78
(−65.61 to − 9.95)
0.01−0.16
(−2.19, 1.88)
0.88−21.12
(−49.24, 7.00)
0.140.61
(−1.38, 2.60)
0.54
Tricyclics78.65
(59.44 to 97.85)
<0.0010.55
(−0.17, 1.27)
0.14−0.96
(−35.41 to 33.49)
0.96−1.68
(−4.20, 0.84)
0.19−4.73
(−39.54, 30.08)
0.791.89
(−0.58, 4.35)
0.13
  • NICE, National Institute for Health and Care Excellence; SSRI, selective serotonin reuptake inhibitor.